Glaucoma Journal Club

In this database

7

2015 โ€“ 2024

DB Citations

88

across indexed articles

h-index

โ€”

Not available

Total Citations

โ€”

Not available

7 articles in Glaucoma Journal Club

Corneal Hysteresis for the Diagnosis of Glaucoma and Assessment of Progression Risk: A Report by the American Academy of Ophthalmology.

Corneal hysteresis is lower in glaucoma patients compared with normal subjects, and lower CH is associated with an increased risk of disease progression.

Ophthalmology2023 Apr29 citations
iop-medical-therapyglaucoma-diagnosis

Trabecular Procedures Combined with Cataract Surgery for Open-Angle Glaucoma: A Report by the American Academy of Ophthalmology.

Trabecular procedures combined with cataract surgery provide an additional mild IOP reduction over cataract surgery alone in hypertensive OAG subjects.

Ophthalmology2024 Mar21 citations
iop-medical-therapyglaucoma-surgery

Central Visual Field Testing in Early Glaucoma: A Report by the American Academy of Ophthalmology.

Evidence to date does not support routine testing using 10-2 VF for patients with early glaucoma.

Ophthalmology2024 Feb17 citations
visual-fieldoptic-nerve

Selective Laser Trabeculoplasty for the Treatment of Glaucoma: A Report by the American Academy of Ophthalmology.

Based on level I evidence, SLT is an effective long-term option for the treatment of open-angle glaucoma and is equivalent to ALT.

Ophthalmology2024 Jan17 citations
iop-medical-therapylaser-treatment

Aqueous Shunts with Extraocular Reservoir for Open-Angle Adult Glaucoma: A Report by the American Academy of Ophthalmology.

Implantation of aqueous shunts with extraocular reservoir, including valved or nonvalved devices, has been shown to be an effective strategy to lower IOP.

Ophthalmology2024 Feb4 citations
glaucoma-surgeryiop-medical-therapy

Proteomic Analysis of Macular Fluid Associated With Advanced Glaucomatous Excavation.

JAMA ophthalmology2016 Jan

Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.

Level I evidence indicates that intravitreal anti-VEGF pharmacotherapy is safe and effective over 2 years for ME associated with CRVO and that delay in treatment is associated with worse visual outcomes.

Ophthalmology2015 Apr